Pseudomonas aeruginosa is a dominant pathogen in people with cystic fibrosis (CF)
contributing to morbidity and mortality. Its tremendous ability to adapt greatly facilitates its …

Chronic lower airway infection with Pseudomonas aeruginosa is a major contributor to
morbidity and mortality in individuals suffering from the genetic disease cystic fibrosis (CF) …

Background Respiratory tract infections with Pseudomonas aeruginosa occur in most
people with cystic fibrosis (CF). Established chronic P aeruginosa infection is virtually …

Pseudomonas aeruginosa is a remarkably versatile environmental bacterium with an
extraordinary capacity to infect the cystic fibrosis (CF) lung. Infection with P. aeruginosa …

Pseudomonas aeruginosa opportunistically infects the airways of patients with cystic fibrosis
and causes significant morbidity and mortality. Initial infection can often be eradicated …

Rationale: New isolation of Pseudomonas aeruginosa (Pa) is generally treated with inhaled
antipseudomonal antibiotics such as tobramycin inhalation solution (TIS). A therapeutic …

The past decade has seen significant advances in understanding of the pathogenesis and
progression of lung disease in cystic fibrosis (CF). Pulmonary inflammation, infection, and …

Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen, designated by the
World Health Organization as a critical priority for development of new therapeutics due to …

Introduction: Cystic fibrosis is an autosomal recessive disorder caused by mutations in the
cystic fibrosis transmembrane conductance regulator (CFTR) gene that codes for the CFTR …

Background Inhaled antibiotics are commonly used to treat persistent airway infection with
Pseudomonas aeruginosa that contributes to lung damage in people with cystic fibrosis …